ASCO 2020：11项中国研究课题入选口头报告，17项Poster报告

受全球新冠疫情冲击，月初于5年初29日~6年初2日在芝加哥移师的美国医学学就会（ASCO）年就会本年将首次以直通上形式举办，这是目前最大规模的直通上盛就会。今天，就决议的简介作答公布，共103个sessions，我国共有11项研究工作荣膺口头报告，17项荣膺Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或卡马替尼加卡培他滨使用HER2+前列腺肿瘤乳腺肿瘤（PHOEBE）：一项III期随机飞行测试。

专场：前列腺肿瘤乳腺肿瘤

所作：我国医学科学院病房徐兵河系主任、马飞系主任，北京大学附属病房胡夕春系主任等

简介号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可开刀三同义乳腺肿瘤标准治疗后卡培他滨确保节拍治疗的III期飞行测试（SYSUCC-001）。

专场：乳腺肿瘤—局部/地区/专用治疗

所作：香山大学防疫教育之前心王树森系主任等

简介号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用前列腺肿瘤脑的表型相似性来预见脑脊液之前循环DNA监测的概率: 新工具对抗老对手

专场：新工具消除老问题

所作：李美芹 李德兰等

简介号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为之前期肝蛋白肿瘤的一直通治疗：一项全站标签、随机、多教育之前心II/III期飞行测试。

专场：胃部肠道肿瘤—胃部食管、凋亡和肝胆

所作：中国大学特罗斯季亚涅齐病房毕锋系主任、我国国民解放军八一病房秦叔逵系主任等

简介号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

我国之前期肝肿瘤患儿阿帕替尼二直通治疗：一项随机、低剂量对照、双盲III期研究工作

专场：胃部肠道肿瘤—胃部食管、凋亡和肝胆

所作：我国国民解放军八一病房秦叔逵系主任、中国大学特罗斯季亚涅齐病房李秋系主任等

简介号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

之前期散光卵巢肿瘤二次蛋白减灭术的一项随机III期飞行测试：SOC1 / SGOG-OV2。

讲座：内科肿瘤症

所作：北京大学附属香山病房臧荣余系主任等

简介：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈肿瘤根治性阴囊切除术后专用治疗之前的序贯放治疗对比单独放疗或同步放治疗（STARS研究工作）：一项随机、对照、全站标签的III期飞行测试。

就决议：内科肿瘤症

所作：香山大学防疫教育之前心黄鹤系主任、刘继红系主任等

简介号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：专用吉非替尼对比治疗使用可切除的EGFR突变的N1-N2期NSCLC-随机III期医学飞行测试的最终总体生存数据分析。

讲座：肺肿瘤—非小蛋白局部-地区/小蛋白/其他臀部

所作：广东省国民病房吴一龙系主任等

简介号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变寡分散非小蛋白肺肿瘤患儿一直通嘧啶还原酶抑制剂共同或不共同积极前直通局部放疗：III期全站标签医学随机飞行测试（SINDAS）的之前期结果（NCT02893332）。

讲座：肺肿瘤-非小蛋白分散

所作：四川省国民病房曾铭系主任等

简介：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对某类死亡-1（PD-1）的人源化IgG4单克隆抗体共同阿昔替尼使用前列腺肿瘤呼吸道乳肿瘤患儿的Ib期研究工作的总生存期和脊椎动物标志物数据分析。

讲座：乳肿瘤/皮肤肿瘤

所作：北京大学病房郭军、盛锡楠系主任等

简介：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的耐用性和结果：通用CAR-T蛋白首次生理飞行测试治疗复发/难治性T蛋白急性淋巴蛋白前列腺癌（r/r T-ALL）的耐用性和。就决议：开发之前的治疗技术-免疫治疗。所作：王欣欣等简介：3013年初历：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在之前期食管鳞状蛋白肿瘤患儿之前的广泛应用：一项随机的全站标签II期飞行测试（ORIENT-2）。就决议：胃部肠道肿瘤-胃部食管肿瘤、凋亡肿瘤和肝胆道肿瘤所作：徐建明系主任等简介：4511年初历：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D抗体CAR-T蛋白对髓母蛋白瘤的根除性治疗就决议：之前枢神经系统所作：代红久、孙斌、杨东、徐晖、顾美美、魏佳、赵旭东简介：2522年初历。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在之前期错配修复缺陷患儿之前的广泛应用就决议：开发之前的治疗学-免疫治疗所作：沈琳系主任等简介：3021年初历。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART治疗复发/难治性ACUTE淋巴蛋白前列腺癌/淋巴瘤的首例生理医学飞行测试就决议: 开发性治疗学-免疫治疗所作简介：张明志，白水等简介：3026年初历: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）共同广泛使用之前期虚拟瘤患儿的Ib期研究工作就决议：发展性治疗学--化学键靶向药物和脊椎动物学所作：龚继芳，沈琳系主任等简介：3523年初历：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin共同紫杉醇和nedaplatin治疗散光或前列腺肿瘤食管鳞状蛋白肿瘤（ESCC）患儿的II期研究工作。就决议：胃部肠道肿瘤-胃部食管、凋亡和肝胆道肿瘤的研究工作所作：王志强，李玉红，王德申，王凤华，任超，谭琼 王志强、李玉红、王德深、王凤华、任超、谭琼简介：4522年初历：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.就决议：胃部肠道肿瘤-胃部食管肿瘤、凋亡肿瘤和肝胆管肿瘤的二直通治疗所作：宋艳等简介：4524年初历：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体环状RNA均值使用初始切除时监测高等级肿瘤的尿液外体环状RNA均值：一项多教育之前心的回顾性研究工作就决议：泌尿生殖系统肿瘤症--肿瘤、阴囊颈肿瘤和肿瘤所作简介：Liaoyuan Li等简介：5522年初历。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 局部之前期宫颈肿瘤并发治疗后的专用治疗就决议: 内科肿瘤症所作简介： 李珉珉等简介：6031年初历：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼治疗甲状腺髓性肿瘤的相关性：基于ALTER01031飞行测试的数据分析。就会话：头颈部所作：济南市病房得意系主任简介：6526年初历。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄组对安洛替尼治疗后患儿故事情节的冲击: ALTER01031的亚组数据分析就决议：头颈部所作：济南市病房得意系主任简介：6527年初历。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA数据分析预见I-IIIA期非小蛋白肺肿瘤（NSCLC）患儿术后复发: GASTO1035和GASTO1018的结果就决议：肺肿瘤-非小蛋白局部-地区性/小蛋白/小蛋白/其他胸科肿瘤症所作：Si-Yu Wang等简介：9023年初历：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白肺肿瘤（NSCLC）之前EGFR嘧啶还原酶抑制剂的新型耐药系统就决议:肺肿瘤-非小蛋白前列腺肿瘤肺肿瘤所作简介：赵昕，金玲玲，满宇，欧春花，金兰，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧春花、金兰、薛武、杨绍、范敏简介：9528年初历：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1飞行测试之前之前期乳肿瘤总生存的替代终点就决议：乳肿瘤/皮肤肿瘤所作：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟简介：10030年初历：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼治疗复发或前列腺肿瘤原发性恶性骨患儿的II期研究工作就决议： 性疾病所作：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶简介：11525年初历。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评分安罗替尼在之前期性疾病患儿多直通治疗之前的耐用性和。就决议：性疾病所作：姚伟涛，王家强，张鹏，王欣，杜新辉，田志浩，牛晓颖 姚伟涛、王家强、张鹏、王鑫、杜鑫辉、田志超、牛晓英简介：11526年初历：414